Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4587 - Cognitive function changes and Associated Factors in Patients Receiving Chemotherapy

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Elif Dil

Citation

Annals of Oncology (2019) 30 (suppl_5): v836-v845. 10.1093/annonc/mdz276

Authors

E. Dil1, G. Bagcivan2

Author affiliations

  • 1 Medical Oncology, Istanbul Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi, 34668 - Istanbul/TR
  • 2 School Of Nursing, Koc University, 34010 - Istanbul/TR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4587

Background

Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies.In recent years, growing attention is being paid to the potential adverse effects of chemotherapy on brain and cognitive function. Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies. The aim of the study is to evaluate cognitive function changes experienced by cancer patients who receive chemotherapy and associated factors.

Methods

This is a descriptive study. The data collection phase of the study is ongoing and the results obtained from 47 patients who received chemotherapy have been reported here. The results of the large group will be presented at the congress. Data collection was started on March 2019 and will be continuing until September 2019. This study was conducted in a Research and Training Hospital in Istanbul/Turkey. Data were collected by using the Patient İnformation form and Functional Assessment of Chronic Illness Therapy- Cognitive Function (FACIT-Cog) and The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.

Results

There was statistically significant and positive relationship between FACIT-Cog “perceived cognitive impairments” subscale and EORTC-30 cognitive (r = 0,755; p ≤ 0,001), emotional (r = 0,505; p = 0,001) and social (r = 0,504; p = 0,001) functioning subscales. There was statistically significant and positive relationship between FACIT-Cog “comments from others on cognitive function” and EORTC-30 emotional (r = 0,491; p = 0,001), cognitive (r = 0,539; p ≤ 0,001), and social (r = 0,588; p ≤ 0,001) functioning subscales. FACIT-Cog scores was not significantly differ by patients’ characteristics (p > 0,005).

Conclusions

Cognitive function should be assessed and considered during the care of cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.